Protalex, Inc. (PRTX) Announces Interim Findings From U.S. Phase 1(b) Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients
2/10/2014 8:10:51 AM
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, today announced preliminary findings from a limited interim analysis of its U.S.-based multicenter Phase 1(b) randomized, multiple-dose, dose-escalation study of PRTX-100 in combination with methotrexate or leflunomide in adults with active rheumatoid arthritis (PRTX-100-104 Study). PRTX-100 is an investigational drug incorporating a highly purified form of Staphylococcal Protein A. The interim analysis included patients in the first four dosing cohorts of the five-cohort study through day 85 of the study protocol.
Help employers find you! Check out all the jobs and post your resume.
comments powered by